Carlos Linn

420 total citations · 1 hit paper
15 papers, 283 citations indexed

About

Carlos Linn is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Reproductive Medicine. According to data from OpenAlex, Carlos Linn has authored 15 papers receiving a total of 283 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 3 papers in Reproductive Medicine. Recurrent topics in Carlos Linn's work include Lung Cancer Treatments and Mutations (4 papers), Advanced Breast Cancer Therapies (3 papers) and Ovarian cancer diagnosis and treatment (3 papers). Carlos Linn is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Advanced Breast Cancer Therapies (3 papers) and Ovarian cancer diagnosis and treatment (3 papers). Carlos Linn collaborates with scholars based in United States, China and South Korea. Carlos Linn's co-authors include Joohyuk Sohn, Elena Poddubskaya, Leslie M. Randall, Giovanni Scambia, Kan Yonemori, Amit M. Oza, Yaroslav Shparyk, Ross Stewart, Bradley J. Monk and Julia Perkins Smith and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Carlos Linn

14 papers receiving 282 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial

2021 160 citations Bradley J. Monk, Nicoletta Colombo et al. The Lancet Oncology profile →

Peers

Carlos Linn

ONCOL

IMMUN

PRM

Sebastien Hazard United States

Maria Kfoury France

Sammy Yuan United States

Kotaro Shimura Japan

Daron Street United States

Elena Giudice Italy

Beata Maćkowiak-Matejczyk Poland

Alejandra Wernicke Argentina

Ningning Li China

Justin Harold United States

Sebastien Hazard United States

Carlos Linn

254 ×1.3

ONCOL

93 ×0.9

28 ×0.3

IMMUN

142 ×1.6

PRM

58 ×1.7

Citations per year, relative to Carlos Linn Carlos Linn (= 1×) peers Sebastien Hazard

Countries citing papers authored by Carlos Linn

Since Specialization

Citations

This map shows the geographic impact of Carlos Linn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Linn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Linn more than expected).

Fields of papers citing papers by Carlos Linn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Linn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Linn. The network helps show where Carlos Linn may publish in the future.

Co-authorship network of co-authors of Carlos Linn

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Linn. A scholar is included among the top collaborators of Carlos Linn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Linn. Carlos Linn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Street, Daron, David Starks, Haider Mahdi, et al.. (2024). A phase I/II study of maplirpacept in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (OC): Phase 1 results.. Journal of Clinical Oncology. 42(16_suppl). e17546–e17546. 2 indexed citations

Cox, Donna S., Lien Van Eyck, Sylvester Pawlak, et al.. (2023). Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults. British Journal of Clinical Pharmacology. 89(9). 2867–2876. 9 indexed citations

Xu, Binghe, Huiping Li, Qingyuan Zhang, et al.. (2021). Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2– advanced breast cancer in Chinese women. Cancer Chemotherapy and Pharmacology. 88(1). 131–141. 11 indexed citations

Monk, Bradley J., Nicoletta Colombo, Amit M. Oza, et al.. (2021). Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. The Lancet Oncology. 22(9). 1275–1289. 160 indexed citations breakdown →

Ledermann, Jonathan A., Nicoletta Colombo, Amit M. Oza, et al.. (2020). 1 Avelumab in combination with and/or following chemotherapy vs chemotherapy in treatment-naive patients with ovarian cancer: biomarker analyses from the phase 3 JAVELIN Ovarian 100 trial. A1.1–A1. 5 indexed citations

Ledermann, JA, Amit M. Oza, Kenji Fujiwara, et al.. (2020). Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial. Gynecologic Oncology. 159. 13–14. 43 indexed citations

Sun, Wan, Wěi Li, Shusen Wang, et al.. (2018). Abstract CT048: Biomarker analysis from a phase 1 study of palbociclib (PAL) plus letrozole (L) as first-line treatment for ER+/HER2– advanced breast cancer (ABC) in Chinese women. Cancer Research. 78(13_Supplement). CT048–CT048. 1 indexed citations

Shen, Lin, Yan Sun, Jianming Xu, et al.. (2017). Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors. Oncology and Therapy. 5(2). 171–180. 3 indexed citations

Li, Huiping, Qingyuan Zhang, Shusen Wang, et al.. (2017). Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study. The Lancet Oncology. 18. S7–S7. 4 indexed citations

10.

Shen, Lin, Shukui Qin, Yan Sun, et al.. (2015). Sunitinib in Chinese patients with advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology. 33(15_suppl). e15208–e15208. 3 indexed citations

11.

Chang, Gee‐Chen, Chun-Ming Tsai, Te‐Chun Hsia, et al.. (2013). Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: An open-label single-arm study. Journal of the Formosan Medical Association. 112(9). 518–526. 1 indexed citations

12.

Ahn, Myung‐Ju, James Chih‐Hsin Yang, Qingyu Xiu, et al.. (2012). Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer. 77(2). 346–352. 22 indexed citations

13.

Chen, Jen‐Shi, Yee Chao, Yung‐Jue Bang, et al.. (2010). A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. Anti-Cancer Drugs. 21(8). 777–784. 17 indexed citations

14.

Liang, Jun, Mi Sun Ahn, Qingyu Xiu, et al.. (2010). First-line treatment (txt) with pemetrexed-cisplatin (PC), followed sequentially by gefitinib (G) or pemetrexed, in Asian, never-smoker (n/smkr) patients (pts) with advanced NSCLC: An open-label, randomized phase II trial.. Journal of Clinical Oncology. 28(15_suppl). 7591–7591. 2 indexed citations

15.

Meißner, Andreas, et al.. (2008). Defibrinierungssyndrom nach Schlangenbißverletzungen. DMW - Deutsche Medizinische Wochenschrift. 114(39). 1484–1487.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact